Implant infection, rupture and capsular contracture

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

An implant can develop a problem soon after surgery or years after apparently satisfactory reconstruction. The same visible enlargement can reflect bleeding, early postoperative fluid, infection, a shell problem or a late pathological effusion. Start with the patient's physiology and the chronology: when the implant was placed, when the change began, how quickly it progressed and whether there is a wound opening, discharge, fever or a discrete lump. Ask about previous implants and revisions, radiotherapy and the device details where available. Describing every change as an implant complication can also miss an independent breast or chest-wall cancer. Examine the skin, scars, reconstructed mound and regional nodes, comparing with the other side and earlier documented findings.

The immediate objective is to decide what must happen now and what can be investigated through a planned specialist pathway. Deep infection and threatened soft-tissue coverage can jeopardise the reconstruction and require surgery; rupture without infection is usually an imaging and reconstructive decision rather than automatic sepsis treatment. Contracture is a tightening capsule associated with firmness, distortion and sometimes pain, but that label should follow assessment of a new change. The patient may fear cancer, losing the reconstruction or being blamed for a previous cosmetic procedure. A clear explanation of the diagnostic question and a named route for obtaining the result helps avoid repeated consultations in which no clinician takes responsibility for the unresolved finding.

Key points

A painful red reconstructed breast, fever, wound discharge or implant exposure needs prompt reconstructive-team assessment. Suspected deep pocket infection requires antimicrobial treatment and a source-control decision; a cellulitis prescription alone is insufficient.
For a persistent new peri-implant seroma more than one year after insertion, arrange urgent ultrasound and purposeful sampling for cytology and appropriate haematopathology, specifically raising BIA-ALCL. Do not simply drain and discard the fluid.
Ultrasound is the initial implant-complication study; equivocal rupture findings warrant dedicated non-enhanced implant MRI. Painful firmness and distortion may represent contracture but a new fluid collection or mass needs separate assessment.
If a surgeon confirms only superficial cellulitis in a stable adult, oral flucloxacillin may be appropriate after allergy, renal, interaction and MRSA checks. This is not a regimen for an infected prosthetic pocket.
BIA-ALCL, rare capsule-associated SCC and systemic symptoms described as breast implant illness are different problems. Their reported associations do not establish a single mechanism or guarantee improvement after explantation.
Preserve implant identification and communicate imaging, sample and operation results. Asymptomatic people do not routinely need prophylactic explantation or en-bloc capsulectomy solely because they have an implant.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Microbial contamination

Postoperative wound breakdown, infected fluid and contact with an exposed device can sustain infection around an implant. The covering tissue and the prosthetic pocket both require assessment when selecting treatment.

Mechanical shell disruption

An implant shell can fail after injury or over time. Earlier devices and previous rupture may complicate interpretation of current silicone-related imaging appearances and should be included in the history.

Excess capsule contraction

An exaggerated tightening of the surrounding scar layer can distort the reconstructed mound and cause discomfort. Previous radiotherapy is relevant when considering both the presentation and revision options.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
An incompletely controlled source
Antibiotics directed at skin bacteria do not remove purulent fluid, dead covering tissue or an exposed infected device. Persistent local infection can therefore continue despite partial improvement in surface redness.
2
Silicone outside the shell
The implant shell contains the fill; the surrounding scar capsule is the body's fibrous envelope. After shell rupture, intracapsular silicone remains within that capsule, whereas extracapsular silicone passes beyond it and may migrate. Silicone in an axillary node alone does not establish current shell rupture.
3
Restricted implant expansion
A tightening capsule limits the implant's ability to conform to the surrounding breast envelope. Firmness, altered position and progressive distortion may be accompanied by pain rather than simple aesthetic dissatisfaction.
4
Capsule-associated lymphoid disease
BIA-ALCL arises in association with the implant capsule and often produces a late effusion. Diagnosis integrates cytological morphology with immunophenotyping, because CD30 can also be expressed by reactive immune cells.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Deep infection and threatened coverageRed flag

Look for spreading warmth and erythema, escalating pain, wound discharge, dehiscence and visible or threatened implant exposure. Fever, tachycardia, hypotension or systemic deterioration increase urgency, but a patient can have a clinically important infected pocket without all of those signs. Inspect the quality of the covering skin and consider an underlying collection. Contact the responsible breast or plastic surgical service promptly and use emergency assessment for systemic illness. A superficial skin response to antibiotics does not prove that a deeper collection or contaminated device has been dealt with.

Shell failure and altered contour

Ask about a new shape change, local discomfort or a lump, and whether any previous implant has ruptured. A breached saline implant loses fluid and visibly deflates; silicone rupture may be silent, so a preserved contour does not establish shell integrity. Silicone-related appearances in lymph nodes can reflect migration or gel bleed and do not, in isolation, establish current shell rupture. The imaging request should specify the implant question and relevant device history so that an appropriate ultrasound assessment is performed. If cancer is clinically suspected, retain the cancer diagnostic pathway rather than limiting the examination to implant integrity. A confident structural diagnosis and the patient's symptoms should guide the subsequent reconstructive consultation.

A contracting scar capsule

All implants become surrounded by a tissue capsule; the existence of that layer is different from symptomatic capsular contracture. Progressive tightness can make the mound firmer, change the implant position and produce an unnatural contour or pain. Previous radiotherapy is relevant to both the risk and the options for revision. Describe the patient's actual functional and cosmetic burden rather than assigning a treatment from a label alone. A new swelling, focal mass, inflammatory change or unexplained node is not adequately explained by firmness and needs an appropriate investigation before revision is planned.

Late fluid and uncommon malignancy

A persistent late effusion, especially beyond one year, calls for assessment for BIA-ALCL as well as infection, rupture and other causes. Most breast symptoms in implant recipients are not this lymphoma, but reassurance requires adequate assessment rather than a prevalence argument. The current MHRA also describes rare reports of capsule-associated SCC and other lymphomas. These are distinct diagnoses. Systemic symptoms sometimes called breast implant illness should be taken seriously and assessed for other causes; present uncertainty honestly without promising that removal will cure fatigue, joint pain or cognitive symptoms.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Ultrasound and directed peri-implant samplingFirst step
Why
For late persistent swelling, obtain urgent expert ultrasound to identify fluid, a capsular mass and relevant nodes. Arrange image-guided aspiration with the laboratory pathway agreed in advance; clearly state concern for BIA-ALCL.
Interpretation and limitations
Send the safely obtainable effusion for dedicated cytology and indicated haematopathology, with microbiology as appropriate. Abnormal morphology and the immunophenotype matter: CD30 expression alone is not diagnostic. A negative or reactive sample does not end the assessment when clinical or imaging suspicion persists.
02
Infection severity and source assessment
Why
Record observations and clinical perfusion, examine the wound and skin envelope, and obtain blood tests and cultures according to the patient's systemic illness and available infected fluid or tissue. Use ultrasound when it will help define a collection.
Interpretation and limitations
A reassuring isolated inflammatory marker cannot exclude a device-pocket problem. Collect useful microbiology before antibiotics when feasible without delaying urgent treatment; source control and the patient's clinical trajectory determine the next step more than a swab result alone.
03
Dedicated implant integrity MRI
Why
Request non-enhanced MRI with the breast implant protocol when ultrasound is equivocal for rupture, including the current and prior implant history. This answers an integrity question rather than automatically substituting for a cancer MRI protocol.
Interpretation and limitations
A normal or unequivocally ruptured implant on adequate ultrasound does not routinely require this additional study. An isolated silicone-containing node in an otherwise asymptomatic breast does not by itself justify escalating to an integrity MRI.
04
Concordant tissue and multidisciplinary review
Why
Biopsy an appropriate solid lesion and review suspicious or confirmed implant-associated malignancy with the specialist breast and haemato-oncology team. Reconcile symptoms, imaging and pathology before definitive oncological surgery.
Interpretation and limitations
Confirmed BIA-ALCL requires tertiary management and staging. Persistent discordance after a reactive fluid result may need repeat targeted assessment, further imaging or another tissue strategy; an inadequately handled aspirate cannot safely be treated as a definitive exclusion.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Haematoma or early seroma

Early postoperative enlargement may reflect blood or tissue fluid rather than shell failure. Rapid expansion, tension or threatened skin warrants urgent review, and an infected collection changes the management.

Superficial cellulitis

A skin-limited infection may be suitable for oral treatment after surgical assessment. Ongoing deep pain, fluid, wound opening or systemic deterioration undermines that interpretation and requires escalation.

Capsule-associated malignancy

A persistent late effusion or mass requires investigation for BIA-ALCL and other uncommon capsule malignancies. Neither the age of the implant nor lack of pain excludes a clinically important diagnosis.

Recurrent or new carcinoma

Implant recipients can develop independent breast or chest-wall malignancy. Suspicious clinical findings should receive appropriate triple assessment rather than an investigation limited solely to device integrity.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01Worked caseAn infected pocket with an exposed implantFirst stepTwelve days after reconstruction, a woman has increasing pain, purulent drainage and a small wound opening with the implant visible. Ultrasound shows peri-implant fluid.

1The assessing clinician obtains observations, checks the remaining skin coverage and contacts the reconstructive surgeon urgently. The combination of purulent fluid and exposure establishes a source-control concern even though her blood pressure is currently normal; she is admitted rather than given an isolated community cellulitis course.
2The surgical team provides antimicrobial treatment and takes her to theatre for drainage, debridement and removal of the exposed infected device after assessing the pocket and non-viable covering tissue. Fluid and tissue are sent for microbiology. Keeping the implant would leave the identified source and inadequate coverage unresolved in this case.
3After the procedure her pain and inflammatory signs improve, the wound has viable edges and the culture result guides the continuing antimicrobial prescription. These observed changes support control of this episode; persistent fever, further necrosis or recurrent fluid would prompt reassessment rather than a routine discharge date.
4The result and loss of the implant are explained directly. The team arranges wound follow-up and a later reconstruction discussion when infection and tissue condition permit, and alerts oncology if recovery changes planned adjuvant appointments. Implant loss is acknowledged as a major event rather than disguised as a minor wound issue.

02Clinical caseEquivocal ultrasound after a contour changeSix years after silicone implant reconstruction, a patient reports a new contour change without fever, redness, discharge or systemic illness. Ultrasound cannot confidently establish shell integrity.

1The clinician confirms that the current concern is an implant structural problem, records earlier device changes and reviews for a separate suspicious mass. The radiologist recommends a dedicated non-enhanced implant MRI because ultrasound is equivocal.
2MRI confirms intracapsular rupture. The patient receives an explanation of the result and a reconstructive consultation to compare removal, replacement and the expected consequences for shape, further operations and her preferences. This finding does not call for empiric infection treatment in the absence of infection.
3She chooses replacement after the discussion. At review the revised wound is healed and the new contour is acceptable to her; the device record is updated. Her outcome does not create a rule that every implant must be exchanged at the same age or that an imaging result predicts identical symptoms in every patient.

03Clinical casePainful contracture after radiotherapyA woman with a previously irradiated implant reconstruction develops progressive firmness, superior distortion and discomfort in clothing. Assessment finds no new effusion, mass or infection.

1The surgeon documents the change in contour and the effect on daily comfort, reviews her previous treatment and agrees that symptomatic contracture is the principal problem. The consultation includes the possibility that further implant surgery may encounter the same compromised tissue environment.
2PreferredAlternativeRevision options and their limits are discussed, including implant removal or replacement and a suitable autologous alternative. After donor assessment she chooses conversion to autologous reconstruction, accepting a longer operation and a donor scar in exchange for her preferred long-term approach.
3Following recovery she reports improved comfort and the flap is healed, with some donor tightness still being addressed. This is an observed individual result, not a guarantee that all pain resolves with conversion or that everyone with contracture requires surgery.

04Clinical caseA new late seroma receives diagnostic samplingA patient notices persistent painless enlargement around an implant inserted eight years earlier. Ultrasound demonstrates a sizeable late effusion.

1The breast service arranges a purposeful ultrasound-guided aspirate and alerts pathology to the BIA-ALCL concern. Fluid is retained for cytology and the appropriate specialist tests rather than discarded after symptom-relieving drainage.
2The sample shows atypical large lymphoid cells with a compatible CD30-positive, ALK-negative immunophenotype. The diagnosis is reviewed by specialist haematopathology and the case is referred to the tertiary multidisciplinary team for staging and treatment planning.
3DefinitiveThe patient receives the verified result and an agreed specialist appointment; the implant history and imaging accompany the referral. The initial diagnostic episode is complete, and the tertiary team takes responsibility for staging and definitive treatment with the patient informed about the next steps.

Key medicines and prescribing safety1 treatment · regimens, roles and cautions

An adult cellulitis option after the reconstructive team confirms a superficial process suitable for oral treatment. It does not treat an exposed infected pocket by itself and does not cover MRSA.

Flucloxacillin 500 mg oral capsules — superficial cellulitis only

For a stable adult with normal renal function, 500 mg orally four times daily for 5 days is a selected NG141 example; the guideline range is 5–7 days. Review improvement within 2–3 days and sooner for deterioration. This example totals 2 g/day. Bristol Laboratories capsules should be taken at least 1 hour before or 2 hours after food with a full glass of water; do not lie down immediately afterwards.

Do not use with beta-lactam hypersensitivity or previous flucloxacillin-associated jaundice/hepatic dysfunction. It is not appropriate for known or suspected MRSA. Suspected deep infection, exposure or systemic illness requires urgent surgical care. If creatinine clearance is below 10 ml/min, reduce the dose or extend the interval; the selected SmPC gives a severe-renal-impairment maximum of 1 g every 8–12 hours. Review methotrexate toxicity risk and monitor INR with warfarin. Liver injury may be delayed; concomitant paracetamol can increase high-anion-gap acidosis risk, especially with renal failure, sepsis or malnutrition.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Reconstruction loss

Infection, necrotic coverage or exposure may make implant removal necessary. Explain the immediate wound plan and preserve a realistic opportunity to reconsider reconstruction after the acute problem has resolved.

Systemic deterioration

A local infection may be accompanied by sepsis or worsening physiological disturbance. Urgent assessment, antimicrobial treatment and source control take precedence over preserving a cosmetic result.

Persistent pain or deformity

Contracture and structural failure can impair comfort and appearance and may require revision. Repeat surgery has its own risks, and recovery should be judged against the patient's stated goals.

Delayed cancer treatment

Wound problems or an unrecognised capsule malignancy can postpone appropriate care. Clear responsibility for reviewing pathology, arranging multidisciplinary discussion and explaining results reduces avoidable diagnostic and treatment delays.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Reassess the whole patient and the covering tissue after infection treatment: observations, pain, wound edges, drainage and any residual fluid. A settling patch of redness is insufficient evidence of cure if discharge or exposure continues.
For the explicitly selected superficial-cellulitis pathway, check that symptoms begin to improve within 2–3 days and arrange earlier assessment for worsening. Review cultures and antibiotic adverse effects; ongoing deep pain or a new collection changes the original diagnosis.
Ensure that imaging and cytology results reach a named clinician who checks concordance and informs the patient. Persistent or recurrent late swelling after a reactive sample needs reassessment, rather than serial drainage without revisiting the differential diagnosis.
After revision, record the new device or reconstruction and review the patient's symptoms and goals as well as wound healing. Continue indicated cancer follow-up and investigate new changes; an implant-health discussion does not replace the person's oncological surveillance plan.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Coverage changes the decision

An exposed implant is not equivalent to an intact reconstruction with a small area of superficial cellulitis. The ability to obtain healthy coverage is part of the surgeon's source-control assessment.

One scan, one question

A non-enhanced implant integrity MRI answers a different question from contrast-enhanced assessment of a suspicious lesion or established malignancy. State the diagnostic purpose clearly on the request.

Fluid deserves a destination

The first late-seroma aspirate is an opportunity for diagnosis. Planning containers and laboratory handling before aspiration is more useful than discovering afterwards that only a routine bacterial swab was sent.

An operation has its own harms

Discussing implant removal includes operative risk, the likely postoperative appearance and uncertainty about symptom improvement. The need for an oncological capsule excision cannot be extrapolated to every worried asymptomatic patient.

11Common pitfallsFrequent interpretation and management errors.

01
Giving a standard skin-infection course and routine follow-up for purulent pocket fluid, wound breakdown or an exposed implant.
02
Ordering MRI for every silicone-containing lymph node, or assuming a normal integrity study excludes all causes of a suspicious breast symptom.
03
Diagnosing BIA-ALCL from CD30 positivity alone, or treating one low-volume negative aspirate as conclusive when swelling and clinical concern persist.
04
Using older risk estimates or causal statements to dismiss implant-illness symptoms, promise a cure after explantation, or recommend en-bloc surgery without an appropriate indication.

Find your next topic